Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 13/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 12/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22480717 | 0.86 | ADRB2 (0.47) | CYP3A4MAPK1CYP2D6TSHRCYP1A2 | |
| SCHEMBL26049484 | 0.80 | CYP3A4 (0.49) | CYP3A4MAPK1CYP2D6TSHRHIF1A | |
| SCHEMBL24065695 | 0.78 | CYP3A4 (0.44) | CYP3A4MAPK1CYP2D6TSHRHIF1A | |
| SCHEMBL22490020 | 0.73 | HIF1A (0.45) | CYP3A4CYP2D6TSHRHIF1ANFKB1 | |
| SCHEMBL13439540 | 0.68 | F2RL1 (0.40) | CYP1A2 | |
| SCHEMBL10094481 | 0.67 | KDM5B (0.40) | CYP1A2RAB9A | |
| SCHEMBL22481288 | 0.64 | ADRB2 (0.56) | CYP3A4MAPK1CYP2D6TSHRCYP1A2 | |
| SCHEMBL5383451 | 0.64 | TRIM24 (0.43) | CYP1A2RAB9ALMNANPSR1 | |
| SCHEMBL22480747 | 0.64 | ADRB2 (0.49) | CYP3A4MAPK1CYP2D6TSHRCYP1A2 | |
| SCHEMBL9781951 | 0.62 | ADRB2 (0.58) | CYP3A4MAPK1CYP2D6TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | CYP3A4 1218/4885MAPK1 4205/4885CYP2D6 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.